| case report | Q2782326 |
| scholarly article | Q13442814 |
| P50 | author | Faith Osier | Q21259711 |
| Adrian V. S. Hill | Q22278197 | ||
| Patricia Njuguna | Q28955482 | ||
| Philip Bejon | Q28955486 | ||
| Peter C. Bull | Q47502958 | ||
| Stephen Gerry | Q47504191 | ||
| Simon J. Draper | Q47576805 | ||
| Susanne H Hodgson | Q56786083 | ||
| Thomas Williams | Q56792357 | ||
| Caroline Ogwang | Q56809163 | ||
| Bernhards Ogutu | Q60044476 | ||
| Stephen L. Hoffman | Q60231547 | ||
| Sassy Molyneux | Q60885159 | ||
| Kevin Marsh | Q30102986 | ||
| P2093 | author name string | Daniel Njenga | |
| Anusha Gunasekera | |||
| Eric R James | |||
| Peter F Billingsley | |||
| Sean C Elias | |||
| Adam Richman | |||
| Alex Macharia | |||
| Elizabeth Juma | |||
| Gathoni Kamuyu | |||
| Brett Lowe | |||
| Charles Magiri | |||
| Yonas Abebe | |||
| Michelle Muthui | |||
| Ken Awuondo | |||
| Domtila Kimani | |||
| Andrew O Cole | |||
| Thomas W Rampling | |||
| Alfred Muia | |||
| Marianne Munene | |||
| Amina Salim | |||
| B Kim L Sim | |||
| P2860 | cites work | Protection afforded by sickle-cell trait against subtertian malareal infection | Q24671995 |
| A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs | Q28476638 | ||
| Comparison of clinical and parasitological data from controlled human malaria infection trials | Q28728616 | ||
| Optimization and validation of multi-coloured capillary electrophoresis for genotyping of Plasmodium falciparum merozoite surface proteins (msp1 and 2) | Q42155400 | ||
| Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection | Q44147641 | ||
| Malaria transmitted to humans by mosquitoes infected from cultured plasmodium falciparum | Q44151722 | ||
| Experimental human challenge infections can accelerate clinical malaria vaccine development | Q44156054 | ||
| Efficacy of preerythrocytic and blood-stage malaria vaccines can be assessed in small sporozoite challenge trials in human volunteers | Q44164122 | ||
| The inoculation of semi-immune Africans with sporozoites of Laverania falcipara (Plasmodium falciparum) in Liberia | Q46155492 | ||
| A LONGITUDINAL LONGITUDINAL SURVEY OF NATURAL MALARIA INFECTION IN A GROUP OF WEST AFRICAN ADULTS. I | Q46758991 | ||
| Malaria | Q56420006 | ||
| Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial | Q33317265 | ||
| Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum | Q33380204 | ||
| Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. | Q33434412 | ||
| Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies | Q33548663 | ||
| Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure | Q33935818 | ||
| High diversity and rapid changeover of expressed var genes during the acute phase of Plasmodium falciparum infections in human volunteers | Q34075564 | ||
| Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites | Q34138437 | ||
| Efficient measurement of opsonising antibodies to Plasmodium falciparum merozoites | Q34540211 | ||
| Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe | Q34792326 | ||
| Strategies for detection of Plasmodium species gametocytes | Q35061598 | ||
| A LONGITUDINAL SURVEY OF NATURAL MALARIA INFECTION IN A GROUP OF WEST AFRICAN ADULTS | Q35398476 | ||
| Real-time quantitative reverse transcription PCR for monitoring of blood-stage Plasmodium falciparum infections in malaria human challenge trials | Q35771762 | ||
| Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? | Q36391845 | ||
| ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans | Q36460499 | ||
| Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites | Q36523062 | ||
| Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria | Q36594057 | ||
| Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update | Q36835613 | ||
| Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infection | Q36936348 | ||
| Immunity to malaria: more questions than answers | Q37194482 | ||
| Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area | Q37331599 | ||
| Plasmodium falciparum var gene expression is modified by host immunity | Q37471820 | ||
| Cardiac complication after experimental human malaria infection: a case report | Q37477948 | ||
| Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines | Q37530299 | ||
| Idiopathic acute myocarditis during treatment for controlled human malaria infection: a case report | Q37539836 | ||
| High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya | Q39362550 | ||
| A novel flow cytometric phagocytosis assay of malaria-infected erythrocytes | Q40101484 | ||
| Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum | Q42127731 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Kenya | Q114 |
| malaria | Q12156 | ||
| Plasmodium falciparum | Q311383 | ||
| P304 | page(s) | 686 | |
| P577 | publication date | 2014-12-12 | |
| P1433 | published in | Frontiers in Microbiology | Q27723481 |
| P1476 | title | Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection | |
| P478 | volume | 5 |
| Q55104120 | Acceptability of a herd immunity-focused, transmission-blocking malaria vaccine in malaria-endemic communities in the Peruvian Amazon: an exploratory study. |
| Q36446343 | Antibody profiles to plasmodium merozoite surface protein-1 in Cambodian adults during an active surveillance cohort with nested treatment study |
| Q64972060 | Beyond Blood Smears: Qualification of Plasmodium 18S rRNA as a Biomarker for Controlled Human Malaria Infections. |
| Q38371653 | Building Capability for Clinical Pharmacology Research in Sub-Saharan Africa. |
| Q38607840 | Building an effective malaria vaccine pipeline to address global needs |
| Q37334935 | Changes in Serological Immunology Measures in UK and Kenyan Adults Post-controlled Human Malaria Infection |
| Q38961574 | Considerations for Comprehensive Analyses of Sporozoite-Based Controlled Human Malaria Infection Studies |
| Q26785760 | Control of Invasive Salmonella Disease in Africa: Is There a Role for Human Challenge Models? |
| Q91712984 | Controlled Human Malaria Infection in Semi-Immune Kenyan Adults (CHMI-SIKA): a study protocol to investigate in vivo Plasmodium falciparum malaria parasite growth in the context of pre-existing immunity |
| Q44168331 | Controlled Human Malaria Infection: Applications, Advances and Challenges. |
| Q47210236 | Controlled human infections: A report from the controlled human infection models workshop, Leiden University Medical Centre 4-6 May 2016. |
| Q36871970 | Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01 |
| Q38949194 | Development of replication-deficient adenovirus malaria vaccines |
| Q38872073 | Development of whole sporozoite malaria vaccines |
| Q35211679 | Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres |
| Q93352892 | Ethical challenges posed by human infection challenge studies in endemic settings |
| Q55002323 | Ethical considerations in Controlled Human Malaria Infection studies in low resource settings: Experiences and perceptions of study participants in a malaria Challenge study in Kenya. |
| Q56378326 | Experimental infection of human volunteers |
| Q90665758 | Fast and fierce versus slow and smooth: Heterogeneity in immune responses to Plasmodium in the controlled human malaria infection model |
| Q89794792 | Human unconventional T cells in Plasmodium falciparum infection |
| Q92001627 | Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites |
| Q47271937 | Impact of Sickle Cell Trait and Naturally Acquired Immunity on Uncomplicated Malaria after Controlled Human Malaria Infection in Adults in Gabon |
| Q35052801 | Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies |
| Q37199873 | Infectivity of Plasmodium falciparum in Malaria-Naive Individuals Is Related to Knob Expression and Cytoadherence of the Parasite |
| Q101051271 | Intrinsic multiplication rate variation and plasticity of human blood stage malaria parasites |
| Q60921728 | Is Saglin a mosquito salivary gland receptor for Plasmodium falciparum? |
| Q35559418 | Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya |
| Q37118222 | Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity |
| Q40082198 | Plasmodium falciparum malaria parasite var gene expression is modified by host antibodies: longitudinal evidence from controlled infections of Kenyan adults with varying natural exposure |
| Q28066456 | Plasmodium vivax Controlled Human Malaria Infection - Progress and Prospects |
| Q37361903 | Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines |
| Q36394182 | Recent advances in recombinant protein-based malaria vaccines |
| Q35817470 | Robust, reproducible, industrialized, standard membrane feeding assay for assessing the transmission blocking activity of vaccines and drugs against Plasmodium falciparum |
| Q93148172 | Safety and Differential Antibody and T-Cell Responses to the Plasmodium falciparum Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants |
| Q56349366 | Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Sporozoite Vaccine in Tanzanian Adults |
| Q36644534 | Safety, Immunogenicity, and Protective Efficacy of Intradermal Immunization with Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites in Volunteers Under Chloroquine Prophylaxis: A Randomized Controlled Trial |
| Q92802893 | T cell-mediated immunity to malaria |
| Q28084325 | The March Toward Malaria Vaccines |
| Q46852298 | The frontline of controlled human malaria infections: A report from the controlled human infection models Workshop in Leiden University Medical Centre 5 May 2016. |
| Q38577638 | The march toward malaria vaccines |
| Q28070246 | The role of PfEMP1 as targets of naturally acquired immunity to childhood malaria: prospects for a vaccine |
| Q91967653 | Use of gene expression studies to investigate the human immunological response to malaria infection |
| Q36151198 | Vaccine Strain-Specificity of Protective HLA-Restricted Class 1 P. falciparum Epitopes |
| Q54258053 | What goes around comes around: modeling malaria transmission from humans back to mosquitos. |
| Q55381231 | Whole blood transcriptome changes following controlled human malaria infection in malaria pre-exposed volunteers correlate with parasite prepatent period. |
| Q38598055 | Workshop report: Malaria vaccine development in Europe--preparing for the future. |
Search more.